Acelyrin and Alumis to merge in deal combining cash, assets
After running into clinical hurdles with its “diamond in the rough” strategy, Los Angeles immunology biotech Acelyrin is handing over its last remaining clinical asset and $448 million in cash and equivalents ...
After running into clinical hurdles with its “diamond in the rough” strategy, Los Angeles immunology biotech Acelyrin is handing over its last remaining clinical asset and $448 million in cash and equivalents ...
